{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:38:12Z","timestamp":1772120292721,"version":"3.50.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>JAK1, a member of the JAK kinase family, is involved in the signal transduction of multiple cytokine pathways and is crucial in the onset and progression of inflammation and tumours. Consequently, JAK1 has garnered significant attention in recent years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We use bibliometric and visual analysis to evaluate the thematic trends and knowledge structure of TRPV1\u2019s research papers on JAK1, sourced from the Web of Science core collection from 2003 to 2024. CiteSpace is used to analyze references and keywords of authors, institutions, countries, and commonly cited, and applies co-current and clustering functions to generate visual knowledge maps.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3,686 articles were incorporated. The primary research domain of JAK1 is oncology; the United States leads in publication volume, with the University of Texas holding the most prominent central position. The keyword distribution indicates that the literature on JAK1 from 2003 to 2009 primarily concentrated on mechanistic studies, encompassing gene expression, activation, pathways, and cell apoptosis. From 2008 to 2018, research hotspots predominantly examined the association between JAK1 and various disease atlases. Beginning in 2012 and extending to 2024, the focus shifted towards the research and development of clinical pharmaceuticals, along with their safety and efficacy. Gene expression, signal transduction, atopic dermatitis, and JAK1-selective inhibitors have emerged as prominent research areas in recent years, exhibiting significant potential for development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study presents the contemporary status and prospective trends of JAK1 research over the last two decades. Current research focuses on skin inflammation, rheumatoid arthritis, and tumor-related diseases, while new signaling pathways are constantly being discovered. JAK1 inhibitors are gradually being used in clinical practice and have good development prospects, which will become the main trend of future research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1537508","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:24:46Z","timestamp":1752729886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A bibliometric and visual analysis of Jak1 to explore trends and frontiers"],"prefix":"10.3389","volume":"15","author":[{"given":"Cong","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ensi","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901477","article-title":"Translating JAKs to jakinibs","volume":"204","author":"Gadina","year":"2020","journal-title":"J Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/rheumatology\/keab024","article-title":"JAK1: Number one in the family; number one in inflammation","volume":"60","author":"Spinelli","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232387","article-title":"Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis","volume":"221","author":"Horesh","year":"2024","journal-title":"J Exp Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155141","article-title":"Hexahydrocurcumin from Zingiberis rhizoma attenuates lipopolysaccharide-induced acute pneumonia through JAK1\/STAT3 signaling pathway","volume":"122","author":"Li","year":"2024","journal-title":"Phytomedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.immuni.2024.05.025","article-title":"Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity","volume":"57","author":"Xu","year":"2024","journal-title":"Immunity"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020160","article-title":"JAK2 in myeloproliferative neoplasms: still a protagonist","volume":"15","author":"Bader","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080854","article-title":"Roles of JAK2 in aging, inflammation, hematopoiesis and Malignant transformation","volume":"8","author":"Perner","year":"2019","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.04.014","article-title":"Jak3 and the pathogenesis of severe combined immunodeficiency","volume":"41","author":"O'Shea","year":"2004","journal-title":"Mol Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1586\/era.10.203","article-title":"JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia","volume":"11","author":"Uckun","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-015-1645-z","article-title":"The bibliometric analysis of scholarly production: How great is the impact","volume":"105","author":"Ellegaard","year":"2015","journal-title":"Scientometrics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40037-021-00695-4","article-title":"Bibliometrics: Methods for studying academic publishing","volume":"11","author":"Ninkov","year":"2022","journal-title":"Perspect Med Educ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-017-2300-7","article-title":"Citation-based clustering of publications using CitNetExplorer and VOSviewer","volume":"111","author":"van Eck","year":"2017","journal-title":"Scientometrics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110400","article-title":"IFN\u03b3-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling","volume":"97","author":"Padmanabhan","year":"2022","journal-title":"Cell Signal"},{"key":"B15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41419-023-06287-w","article-title":"METTL3 promotes colorectal cancer progression through activating JAK1\/STAT3 signaling pathway","volume":"14","author":"Sun","year":"2023","journal-title":"Cell Death Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.335","article-title":"Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF\/JAK1\/STAT3 and NF-kB signaling pathways synergistically","volume":"11","author":"Zhang","year":"2021","journal-title":"Clin Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2022.106313","article-title":"CircUBXN7 suppresses cell proliferation and facilitates cell apoptosis in lipopolysaccharide-induced cell injury by sponging miR-622 and regulating the IL6ST\/JAK1\/STAT3 axis","volume":"153","author":"Xu","year":"2022","journal-title":"Int J Biochem Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16158","article-title":"JAK1\/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression","volume":"188","author":"Chen","year":"2020","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1087986","article-title":"JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis","volume":"14","author":"Frede","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117827","article-title":"Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer","volume":"110","author":"Jia","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"B23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12964-024-01550-9","article-title":"CD146(+)CAFs promote progression of endometrial cancer by inducing angiogenesis and vasculogenic mimicry via IL-10\/JAK1\/STAT3 pathway","volume":"22","author":"Yu","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1160719","article-title":"Advances in the role of STAT3 in macrophage polarization","volume":"14","author":"Xia","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010024","article-title":"JAK1 is a novel target of tumor- and invasion-suppressive microRNA 494-5p in colorectal cancer","volume":"16","author":"Patil","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.641271","article-title":"CDK9 inhibitor induces the apoptosis of B-cell acute lymphocytic leukemia by inhibiting c-myc-mediated glycolytic metabolism","volume":"9","author":"Huang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.677169","article-title":"ERO1L is a novel and potential biomarker in lung adenocarcinoma and shapes the immune-suppressive tumor microenvironment","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2013.2017","article-title":"Hospicells promote upregulation of the ATP-binding cassette genes by insulin-like growth factor-I via the JAK2\/STAT3 signaling pathway in an ovarian cancer cell line","volume":"43","author":"Benabbou","year":"2013","journal-title":"Int J Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: Regulator of cell death","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.018","article-title":"Autophagy in inflammation, infection, and immunometabolism","volume":"54","author":"Deretic","year":"2021","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.0c00517","article-title":"Autophagy activation represses pyroptosis through the IL-13 and JAK1\/STAT1 pathways in a mouse model of moderate traumatic brain injury","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201445349","article-title":"STS-1 promotes IFN-\u03b1 induced autophagy by activating the JAK1-STAT1 signaling pathway in B cells","volume":"45","author":"Dong","year":"2015","journal-title":"Eur J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117133","article-title":"Ameliorative effect of Alangium chinense (Lour.) Harms on rheumatoid arthritis by reducing autophagy with targeting regulate JAK3-STAT3 and COX-2 pathways","volume":"319","author":"Xiao","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174121","article-title":"JAK\/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes","volume":"902","author":"Chen","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155392","article-title":"A centric view of JAK\/STAT5 in intestinal homeostasis, infection, and inflammation","volume":"139","author":"Surbek","year":"2021","journal-title":"Cytokine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203287","article-title":"Curcumol may alleviate psoriasis-like inflammation by inhibiting keratinocyte proliferation and inflammatory gene expression via JAK1\/STAT3 signaling","volume":"13","author":"Lv","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00011-022-01686-9","article-title":"Inhibition of gp130 alleviates LPS-induced lung injury by attenuating apoptosis and inflammation through JAK1\/STAT3 signaling pathway","volume":"72","author":"Xu","year":"2023","journal-title":"Inflammation Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156338","article-title":"LncRNA MIR4435-2HG suppression regulates macrophage M1\/M2 polarization and reduces intestinal inflammation in mice with ulcerative colitis","volume":"170","author":"Cao","year":"2023","journal-title":"Cytokine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2020.144268","article-title":"In vivo evaluation of Nano-palladium toxicity on larval stages and adult of zebrafish (Danio rerio)","volume":"765","author":"Anila","year":"2021","journal-title":"Sci Total Environ"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00032.2009","article-title":"JAK redux: a second look at the regulation and role of JAKs in the heart","volume":"297","author":"Kurdi","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/09636897241254678","article-title":"A novel JAK1 inhibitor SHR0302 combined with prednisone for first-line treatment of chronic graft-versus-host disease: A phase I clinical trial","volume":"33","author":"He","year":"2024","journal-title":"Cell Transplant"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","article-title":"Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)","volume":"91","author":"King","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9056","article-title":"Filgotinib, a JAK1 inhibitor, for treatment-resistant rheumatoid arthritis","volume":"322","author":"Singh","year":"2019","journal-title":"JAMA"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata","volume":"87","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa896","article-title":"JAK1 inhibition and inflammatory bowel disease","volume":"60","author":"Harris","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1326281","article-title":"Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","article-title":"Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease","volume":"76","author":"Coskun","year":"2013","journal-title":"Pharmacol Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01717-z","article-title":"Efficacy of Janus kinase inhibitors in rheumatoid arthritis","volume":"72","author":"Langbour","year":"2023","journal-title":"Inflammation Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The Jak\/STAT pathway: A focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2021","journal-title":"Semin Arthritis Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103168","article-title":"JAK inhibitors and systemic sclerosis: A systematic review of the literature","volume":"21","author":"Moriana","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2193682","article-title":"JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review","volume":"16","author":"Muddebihal","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1158\/2159-8290.CD-NB2015-142","article-title":"Ruxolitinib benefits some with pancreatic cancer","volume":"5","year":"2015","journal-title":"Cancer Discov"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052535","article-title":"Effects of ruxolitinib and calcitriol combination treatment on various molecular subtypes of breast cancer","volume":"23","author":"Schneider","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3183","article-title":"Single-cell proteomic profiling identifies combined AXL and JAK1 inhibition as a novel therapeutic strategy for lung cancer","volume":"80","author":"Taverna","year":"2020","journal-title":"Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.08.009","article-title":"Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro","volume":"341","author":"Wilson","year":"2013","journal-title":"Cancer Lett"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2013.0265","article-title":"Pharmacobiological approach for the clinical development of ruxolitinib in myeloproliferative neoplasms","volume":"32","author":"Elia\u00e7\u0131k","year":"2015","journal-title":"Turk J Haematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1537508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T05:24:47Z","timestamp":1752729887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1537508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":69,"alternative-id":["10.3389\/fonc.2025.1537508"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1537508","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"article-number":"1537508"}}